Status:
UNKNOWN
Morphological Changes of Ciliary Body and Trabecular Meshwork
Lead Sponsor:
Yune Zhao
Conditions:
Glaucoma
Myopia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Glaucoma is the leading cause of irreversible blindness worldwide. Although the pathogenesis remains unclear, pathologic increase in intraocular pressure (IOP) due to blocked aqueous outflow through t...
Detailed Description
Glaucoma is the leading cause of irreversible blindness worldwide. Although the pathogenesis remains unclear, pathologic increase in intraocular pressure (IOP) due to blocked aqueous outflow through t...
Eligibility Criteria
Inclusion
- Emmetropia/low myopia,high myopia, primary open-angle glaucoma without high myopia, and high myopia with primary open-angle glaucoma
- have a good gaze to complete the test required inspection;
Exclusion
- hypersensitivity to pilocarpine
- History of eye surgery, including cataract surgery, anti-glaucoma surgery, corneal surgery, retinal surgery, and eye trauma
- history of systemic diseases that may affect the eyes (such as diabetes, hypertension, etc.)
- intraocular chronic inflammatory diseases (uveitis, etc.), retinal diseases (retinal detachment, diabetic retinopathy, retinitis pigmentosa, etc.)
- Corneal scars and severe cataracts affect OCT imaging
- Eye diseases (angle-closure glaucoma, abnormal anterior segment development, neovascularization, etc.) that can affect trabecular meshwork and Schlemm canal structure.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05352854
Start Date
May 1 2022
End Date
August 1 2022
Last Update
April 29 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.